Page 1777 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 101 Natural Killer Cell–Based Therapies 1581

being tested by use of NK cell donor lymphocyte infusions after working to establish proof of concept and to develop exportable
haploidentical HCT in adults with AML. A published study in techniques. Development of platforms that support robust in vivo or
pediatric patients used NK cells as consolidation therapy to maintain ex vivo NK cell expansion and education, selection of NK donors
remissions in a nontransplant setting. This platform is being adapted based on their NK cell receptor genes, manipulation of tumor NK
for testing in elderly AML patients. Additional studies to explore cell receptor ligand expression, and coordination of NK cell interac-
applications in multiple myeloma, lymphoma, and solid tumors are tions with other immune cells are underway at many institutions.
being developed. Ultimately, combination therapy using several strategies will likely
prove most successful. In particular, cytokines such as IL-15, antibod-
ies to block inhibitory receptors, methods to induce adaptive NK
FUTURE DIRECTIONS cells with properties of immune memory, and the use of BiKEs or
TriKEs to make NK cells antigen-specific hold great promise.
Several promising strategies to exploit NK cell alloreactivity to treat
cancer are in development. These include various approaches to
develop in vivo or ex vivo expanded products, manipulations of the REFERENCES
host immune system, and strategies to modify the tumor targets to
enhance their sensitivity to NK cell–mediated killing (Fig. 101.2). 1. Freud AG, Yokohama A, Becknell B, et al: Evidence for discrete stages
Unlike T cells, haplotype mismatched or completely HLA-mismatched of human natural killer cell differentiation in vivo. J Exp Med 203:1033,
NK cells can be given without risk of GVHD, although a recent 2006.
report cautions that conclusion when using highly expanded NK cells 2. Huntington ND, Legrand N, Alves NL, et al: IL-15 trans-presentation
ex vivo using membrane bound IL-15 and 41BB-ligand K562 feeders, promotes human NK cell development and differentiation in vivo. J Exp
because some patients developed a syndrome that histologically and Med 206:25–34, 2009.
40
clinically was indistinguishable from GVHD. Adoptive transfer is 3. Walzer T, Dalod M, Robbins SH, et al: Natural-killer cells and dendritic
limited by the cell dose attained from a single leukopheresis and the cells: “l’union fait la force”. Blood 106:2252–2258, 2005.
current requirement for high dose lymphodepleting chemotherapy. 4. Lopez-Botet M, Angulo A, Guma M: Natural killer cell receptors
In vivo expansion, while detectable, is transient and appears to require for major histocompatibility complex class I and related molecules in
the use of exogenous cytokines such as IL-2, which is associated with cytomegalovirus infection. Tissue Antigens 63:195–203, 2004.
induction of suppressive regulatory T cells. The use of IL-15 (or 5. Liu J, Xiao Z, Ko HL, et al: Activating killer cell immunoglobulin-
IL-15/IL-15Rα complexes to trans present IL-15), the true homeo- like receptor 2DS2 binds to HLA-A*11. Proc Natl Acad Sci USA
static factor for NK cells, is now being tested in patients receiving 111:2662–2667, 2014.
adoptively transferred NK cells to treat their AML or posttransplant 6. Kim S, Poursine-Laurent J, Truscott SM, et al: Licensing of natural killer
relapse. A major advantage of IL-15 is that unlike IL-2, it does not cells by host major histocompatibility complex class I molecules. Nature
stimulate regulatory T cells. Various methods to enrich the NK cell 436:709–713, 2005.
fraction in haploidentical apheresis products are being tested, includ- 7. Raulet DH: Missing self recognition and self tolerance of natural killer
ing depletion of T (CD3) and B (CD19) cells, or positive selection (NK) cells. Semin Immunol 18:145–150, 2006.
+
for CD56 NK cells. Several investigators are also exploring ex vivo 8. Parham P: Taking license with natural killer cell maturation and reper-
NK expansion using EBV-transformed or modified K562 feeder cells toire development. Immunol Rev 214:155–160, 2006.
to increase the infused NK cell dose, potentially circumventing the 9. Joncker NT, Shifrin N, Delebecque F, et al: Mature natural killer cells
need for in vivo expansion. The use of “off-the-shelf” NK cell lines, reset their responsiveness when exposed to an altered MHC environ-
such as NK-92, may provide a large supply of highly cytotoxic NK ment. J Exp Med 207:2065–2072, 2010.
cells that could be used for repeated infusions. Other approaches 10. Elliott JM, Wahle JA, Yokoyama WM: MHC class I-deficient natural
using NK cell products derived from UCB or placental progenitors, killer cells acquire a licensed phenotype after transfer into an MHC class
embryonic stem cells, or induced iPS cell sources are also being I-sufficient environment. J Exp Med 207:2073–2079, 2010.
developed. UCB stem cell–derived ILC that produce IL-22 may 11. Brodin P, Karre K, Hoglund P: NK cell education: not an on-off switch
enhance tissue integrity and improve immune reconstitution after but a tunable rheostat. Trends Immunol 30:143–149, 2009.
HCT. Alternative forms of activation, such as combining NK cells 12. Feuchtinger T, Pfeiffer M, Pfaffle A, et al: Cytolytic activity of NK cell
with either toll-like receptor agonists and/or dendritic cell vaccines, clones against acute childhood precursor-B-cell leukaemia is influenced
are also being explored. Other possibilities are being aimed at sensitiz- by HLA class I expression on blasts and the differential KIR phenotype
ing the target cells using chemotherapy (bortezomib or histone of NK clones. Bone Marrow Transplant 43:875–881, 2009.
deacetylase inhibitors), or irradiation. Lastly, if cytokines such as 13. Di Santo JP: Staying innate: transcription factor maintenance of innate
IL-15 can safely and efficiently expand autologous NK cells in vivo, lymphoid cell identity. Immunol Rev 261:169–176, 2014.
it may be possible to mimic an allogeneic approach by in vivo or ex 14. Horowitz A, Strauss-Albee DM, Leipold M, et al: Genetic and envi-
vivo expansion of NK cells. Combining these with antibodies (anti- ronmental determinants of human NK cell diversity revealed by mass
KIR and anti-NKG2A) that block inhibitory receptors or BiKEs that cytometry. Sci Transl Med 5:208ra145, 2013.
deliver potent activation signals that overcome inhibition through 15. Ruggeri L, Mancusi A, Burchielli E, et al: Effectiveness of donor natural
class I MHC receptors may be incredibly powerful. killer cell alloreactivity in mismatched hematopoietic transplants. Science
295:2097–2100, 2002.
16. Brunstein CG, Wagner JE, Weisdorf DJ, et al: Negative effect of KIR
CONCLUSION alloreactivity in recipients of umbilical cord blood transplant depends
on transplantation conditioning intensity. Blood 113:5628–5634,
The therapeutic use of NK cells is a promising strategy to treat cancer 2009.
in both transplant and nontransplant settings. NK cells have the 17. Willemze R, Rodrigues CA, Labopin M, et al: KIR-ligand incompatibil-
potential to induce graft-versus-tumor effects without inducing ity in the graft-versus-host direction improves outcomes after umbilical
GVHD. To date, the majority of data supporting the antileukemic cord blood transplantation for acute leukemia. Leukemia 23:492–500,
effect of NK cells has emerged from the allo-HCT literature. However, 2009.
the complexities of allo-HCT, including variations in preparative 18. Venstrom JM, Zheng J, Noor N, et al: KIR and HLA genotypes are
regimens, stem cell sources, graft products, posttransplant immune associated with disease progression and survival following autologous
suppression, and disease specific differences all complicate our under- hematopoietic stem cell transplantation for high-risk neuroblastoma.
standing of the underlying biologic mechanisms. This limits the Clin Cancer Res 15:7330–7334, 2009.
design of effective therapies exploiting NK cell alloreactivity. Investi- 19. Yu J, Venstrom JM, Liu XR, et al: Breaking tolerance to self, circulating
gators developing strategies using adoptive transfer of NK cells are natural killer cells expressing inhibitory KIR for non-self HLA exhibit